# Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

> **NCT06184698** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 173 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** liposomal irinotecan
- **DRUG:** 5-FU
- **DRUG:** LV
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06184698
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 173 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184698, "Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06184698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*